000			06038cam a2200469Ii 4500
001			95862
003			ES-MaUEC
005			20230102112725.0
006			m o d
007			cr cnu|||unuuu
008			170426s2017 sz a ob 001 0 eng d
020			_a3319500422 _q(electronic bk.)
020			_a9783319500423 _q(electronic bk.)
020			_z3319500406
020			_z9783319500409 _q(print)
040			_aGW5XE _cGW5XE _dN$T _dEBLCP _dYDX _dUAB _dOCLCO _dESU _dAZU _dUPM _dIOG _dOCLCO _dOCLCF _dVT2 _dOTZ _dOCLCQ _dMERER _dOCLCQ _dOCLCO _dJG0 _dOCLCO _dU3W _dOCLCO _dES-MaUEC _bspa
050		4	_aRM301.25 _b2017 EB
245	0	0	_aTranslating molecules into medicines : _bcross-functional integration at the drug discovery-development interface _cShobha N. Bhattachar, John S. Morrison, Daniel R. Mudra, David M. Bender, editors.
264		1	_aCham, Switzerland _bSpringer _c2017.
300			_a1 recurso en línea (xxiv, 461 páginas) _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aAAPS advances in the pharmaceutical sciences series _x2210-7371 _vvolume 25
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
504			_aIncluye referencias bibliográficas e índice
505	0		_aPreface; Contents; Contributors; About the Editors; Part I: Discovery, Development and Commercialization of Drug Candidates: Overview and Issues; Chapter 1: Pharmaceutical Industry Performance; 1.1 Introduction; 1.1.1 Definitions; 1.1.2 Unmet Need; 1.1.3 NMEs and the Degree of Innovation; 1.2 Drug Discovery and Development Overview; 1.2.1 Learn and Confirm Cycle; 1.2.2 Process to Identify Safe and Effective Medicines; 1.3 How Medicines Work; 1.4 Drug Discovery Strategies: How Medicines Are Discovered; 1.5 Mechanistic Paradox and Precision Medicine; 1.6 Opportunities; References.
505	8		_a3.4.5.1 Application of TE in a Program Exploring Insulin-Degrading Enzyme as a Potential Target for Insulin Sensitization [70]3.4.5.2 Use of TE to Establish Clinical Candidate Performance Characteristics for Aggrecanase Inhibitors as Disease-Modifying ... ; 3.5 Conclusion; References; Chapter 4: In Silico ADME Techniques Used in Early-Phase Drug Discovery; 4.1 Structure-Based In Silico Models; 4.1.1 Molecular Docking; 4.1.2 Molecular Dynamics; 4.2 Ligand-Based In Silico Models and Tools; 4.2.1 Quantitative Structure-Property Relationship (QSPR) Models; 4.2.1.1 Data Set Selection and Curation.
505	8		_a4.2.1.2 Training Set Selection4.2.1.3 Molecular Descriptors; 4.2.1.4 QSPR Model Training/Building; 4.2.1.5 QSPR Model Evaluation; 4.2.1.6 Interpretation of Model Prediction; 4.2.2 ADME QSPR Models Used at Eli Lilly and Company; 4.2.3 Prospective Validation of ADME QSPR Models at Eli Lilly and Company; 4.2.4 Trends Between Calculated Physicochemical Properties and ADME Parameters; 4.2.5 Pharmacophore Modeling; 4.2.6 Site of Metabolism Prediction; 4.2.7 SPR/STR Knowledge Extraction Using Matched Molecular Pair Analysis; 4.3 Integrated and Iterative Use of Models in Early Drug Discovery.
505	8		_aChapter 2: New Product Planning and the Drug Discovery-Development Interface2.1 Overview and Introduction; 2.2 Understanding the Disease State; 2.3 Customer Needs; 2.4 Does Science Matter?; 2.5 The SWOT Team or How to Look Critically at Your Program; 2.6 Those Pesky Competitors; 2.7 How to Have an RandD and Marketing Marriage Made in Heaven; 2.8 Should RandD and Marketing Collaborate Early or Late? Yes!; 2.9 RandD and Marketing Are Allies, Not Enemies; References; Part II: Druggable Targets, Discovery Technologies and Generation of Lead Molecules.
505	8		_aChapter 3: Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies3.1 Introduction; 3.2 Basic Concepts; 3.3 Target Engagement in Vivo; Box 1. Derivation of Eq. (3.5) for Irreversible Inhibitors; 3.4 Application to In Vivo Experimental Design; 3.4.1 Compound Delivery via Pump as a Means to Facilitate Target Validation; 3.4.2 Designing an Osmotic Pump Study; 3.4.3 Approaches to Measuring Target Engagement In Vivo; 3.4.4 The Relationship of TE to Pharmacodynamics; 3.4.5 Case Studies in Using TE.
520	3		_aTackling translational medicine with a focus on the drug discovery development-interface, this book integrates approaches and tactics from multiple disciplines, rather than just the pharmaceutical aspect of the field. The authors of each chapter address the paradox between the molecular understanding of diseases, drug discovery, and drug development. Laying out the detailed trends from various fields, different chapters are dedicated to target engagement, toxicological safety assessments, and the compelling relationship of optimizing early clinical studies with design strategies. The book also highlights the importance of balancing the three pillars: sufficient efficacy, acceptable safety and appropriate pharmacokinetics, all of which are crucial to successful efforts in discovery and development. With discussions regarding the combined approaches of molecular research, personalized medicine, pre-clinical and clinical development, as well as targeted therapies--this compendium is a flexible fit, perfect for professionals in the pharmaceutical industry and related academic fields.
650		7	_aSistemas de liberación de fármacos _2embne _0(OCoLC)fst00898670 _0 _9667667
700	1		_aBender, David M., _eeditor literario
700	1		_aBhattachar, Shobha N., _eeditor literario
700	1		_aMorrison, John S., _eeditor literario
700	1		_aMudra, Daniel R., _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-50042-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017C
998			_b02/2018 _dz _e- _zSI
999			_c95862 _d95862 _x1